Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

CSTL

NASDAQ

Castle Biosciences (CSTL)

33 USD +0.36% vs prior close Oct 14, 2026
Castle Biosciences, Inc. price graph
15 sessions
38 32 14 Sep 14 Oct

The line runs 33.47 USD on 14 September through 33 USD on 14 October, on a scale from 32 to 38. Days the market did not trade hold the previous close, flat.

Market cap
1.0B USD
Revenue, year to Dec 2025
344.2M USD
EPS, diluted, year to Dec 2025
−0.83 USD
52-week range
18 USD – 43 USD
Avg volume
49.9K

as of Oct 14, 2026

Have Castle Biosciences (CSTL) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Castle Biosciences insiders reported 22 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 14 Jul 2026, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 16 Nov 2026

0buys
22sells
$6.06Mnet sold
8other filings
Have Castle Biosciences (CSTL) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
16 Nov 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSell6,942229K USD
11 Nov 2026Juvenal Tobin WChief Commercial OfficerSell6,023211K USD
09 Nov 2026Juvenal Tobin WChief Commercial OfficerSell3,288107K USD
02 Nov 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSell14,496523K USD
28 Oct 2026Juvenal Tobin WChief Commercial OfficerSell6,578240K USD
26 Oct 2026Juvenal Tobin WChief Commercial OfficerSell3,288109K USD
19 Oct 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSell14,496463K USD
12 Oct 2026Juvenal Tobin WChief Commercial OfficerSell3,288111K USD
05 Oct 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerSell14,496516K USD
01 Oct 2026Oelschlager Kristen MChief Operating OfficerSell4,153149K USD
30 Sep 2026Juvenal Tobin WChief Commercial OfficerSell1,03435K USD
29 Sep 2026Juvenal Tobin WChief Commercial OfficerSell5,543197K USD
Sold22 open-market sales177,333$6.06M

Showing the 12 most recent of 22 open-market trades in this window. The figures above count all of them.

8 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Castle Biosciences (CSTL) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
17 Nov 2026BRADBURY DANIELDirectorGift5,985
11 Nov 2026Juvenal Tobin WChief Commercial OfficerOption exercise3,19594K USD
05 Oct 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerOption exercise8,16520K USD
01 Oct 2026Oelschlager Kristen MChief Operating OfficerOption exercise4,15314K USD
21 Sep 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerOption exercise8,58021K USD
11 Sep 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerOption exercise8,58421K USD
01 Sep 2026Oelschlager Kristen MChief Operating OfficerOption exercise4,15214K USD
28 Aug 2026MAETZOLD DEREK JPres. & Chief Exec. OfficerOption exercise12,42830K USD

Which funds hold Castle Biosciences (CSTL)?

8 of the 45 institutional funds we track reported a Castle Biosciences position for the quarter ended 30 Sep 2026 — a combined 69.1M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Castle Biosciences (CSTL)?
FundPositionSharesValueShares q/q
Millennium ManagementAdded495,63317.6M USD+141.3%
AQR Capital ManagementAdded371,78613.2M USD+123.2%
Renaissance TechnologiesHeld (±25%)322,40011.5M USD−13.1%
Citadel AdvisorsHeld (±25%)300,79910.7M USD+13.4%
Two Sigma InvestmentsAdded215,0587.6M USD+114.3%
Man GroupHeld (±25%)99,3653.5M USD−8.6%
D. E. Shaw & Co.Held (±25%)87,5063.1M USD−22.4%
Tudor Investment CorpAdded53,0351.9M USD+266.7%
Point72 Asset ManagementExited

Have members of Congress traded Castle Biosciences (CSTL)?

The most recent congressional trade disclosed in Castle Biosciences is a sale by Josh Gottheimer (house, NJ), dated 15 Mar 2022.

STOCK Act disclosures

Have members of Congress traded Castle Biosciences (CSTL)?
TradedMemberTypeAmountFiled after
15 Mar 2022Josh Gottheimerhouse · Democrat–NJSale1K USD–15K USD33 days
21 Dec 2020Josh Gottheimerhouse · Democrat–NJPurchase1K USD–15K USD17 days

What has been filed or recorded for Castle Biosciences (CSTL)?

The filings we hold for Castle Biosciences, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Castle Biosciences (CSTL)?
And
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.13 USDRevenue $103M
30 Sep 2026FinancialsTotal assets579.4M USDat period end
30 Sep 2026FinancialsTotal equity478.4M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.07 USDRevenue $104M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.49 USDRevenue $84M
31 Dec 2025Annual reportFY 2025 reportedEPS −0.83 USDRevenue $344M
31 Dec 2025FinancialsRevenue344.2M USDfiscal year
31 Dec 2025FinancialsNet income−24.2M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−0.83 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.02 USDRevenue $83M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS 0.15 USDRevenue $86M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.90 USDRevenue $88M
31 Dec 2024Annual reportFY 2024 reportedEPS 0.62 USDRevenue $332M

What do people ask about Castle Biosciences (CSTL)?

From live data
What did Castle Biosciences shares close at?33.00

Castle Biosciences closed at 33.00 USD on 14 Oct 2026, up 0.36% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Castle Biosciences’ market cap?1.0B

Castle Biosciences is worth 1.0B USD by market value as of 14 Oct 2026, which is the share price times the shares on issue from its SEC filings.

What is Castle Biosciences’ revenue?344.2M

Castle Biosciences reported revenue of 344.2M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Castle Biosciences insiders bought or sold shares recently?22 sales

In the 90 days to 22 Nov 2026, Castle Biosciences insiders reported 22 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 14 Jul 2026, show no open-market purchase. A further 8 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Castle Biosciences?8 of 45

8 of the 45 funds we track reported a Castle Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, AQR Capital Management and Renaissance Technologies. See Funds

Have members of Congress traded Castle Biosciences?2 trades

Yes. 2 trades in Castle Biosciences appear in the congressional disclosures we hold; the latest is a sale by Josh Gottheimer (House, NJ) dated 15 Mar 2022, filed 17 Apr 2022. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

When did Castle Biosciences last report earnings?−0.13

Castle Biosciences last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.13 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. Wikimedia CommonsPortraits via Wikimedia Commons. Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain.
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  8. SEC EDGARreported earnings figures and scheduled report dates
  9. SEC EDGARValuation computed from SEC EDGAR filings
  10. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words